Logo

CSL Behring's Haegarda (C1 Esterase Inhibitor) Receives the US FDA's Approval for Pediatric Patients with Hereditary Angioedema

Share this

CSL Behring's Haegarda (C1 Esterase Inhibitor) Receives the US FDA's Approval for Pediatric Patients with Hereditary Angioedema

Shots:  

  • The approval is based on P-lll COMPACT pivotal study and OLE study assessing Haegarda (C1 Esterase Inhibitor- SC) vs PBO in patients aged ≤17yrs. with symptomatic HAE.  
  • Results of COMPACT pivotal study: 95% reduction in the number of HAE attacks- 99% reduction in the use of rescue medication. COMPACT OLE results: all patients experienced a>50% reduction in the number of attacks/ mos. with a 97% reduction in the median number of attacks/ mos. (0.11). All had less than 1 attack/4wks. period and four had >1attack/yr. (one subject was attack free) while no one discontinues the treatment due to AEs
  • Haegarda is a self-administered- plasma-derived concentrate of C1-esterase inhibitor and the only SC therapy approved in the US for routine prophylaxis to prevent HAE attack in patients aged ≥6yrs.

­ Ref: PRNewswire | Image: CSL Behring

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions